Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
Y. Kazansky, H. S. Mueller, D. Cameron, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, P. S. Mundi, Y. Kuwahara, R. Somwar, R. Qu, A. Califano, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, , A. Kentsis
The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.
bioRxiv · May 3, 2024Cancer Biology